Biotech Acquisition Company Warrant
BIOTW
BIOTW was delisted on the 2nd of February, 2023.
48 hedge funds and large institutions have $3.83M invested in Biotech Acquisition Company Warrant in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
1% more capital invested
Capital invested by funds: $3.8M → $3.83M (+$38.3K)
6% less funds holding
Funds holding: 51 → 48 (-3)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.34K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$395 |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$196 |
| 4 |
RA
Ramius Advisors
New York
|
+$59 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.36K |
| 2 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1K |
| 3 |
OCAM
Owl Creek Asset Management
New York
|
-$1K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$960 |
BIOTW Hedge Fund Activity: Q4 2022 in Review
48 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q4 2022, worth a combined $3.83M — up 1% from $3.8M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BIOTW and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was K2 Principal Fund, opening a new position worth an estimated $2.34K. The largest seller was Citadel Advisors, cutting an estimated $1.36K.
- 48 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q4 2022, down from 51 in Q3 2022.
- Funds reported $3.83M of Biotech Acquisition Company Warrant stock for Q4 2022, up 1% quarter-over-quarter.
- 2 funds opened new Biotech Acquisition Company Warrant positions in Q4 2022 and 4 closed out, a net change of -2 holders.
- The largest Biotech Acquisition Company Warrant buyer in Q4 2022 was K2 Principal Fund, an estimated $2.34K added.
- The largest Biotech Acquisition Company Warrant seller in Q4 2022 was Citadel Advisors, an estimated $1.36K sold.
Based on aggregated 13F filings for Q4 2022.